Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NSD2 | O96028 | 1/20 | 0.32 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.32 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.32 |
| ▸ | PDE4A | P27815 | 1/20 | 0.32 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.32 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.32 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.32 |
| ▸ | PADI1 | Q9ULC6 | 1/20 | 0.32 |
| ▸ | PADI3 | Q9ULW8 | 1/20 | 0.32 |
| ▸ | PADI4 | Q9UM07 | 1/20 | 0.32 |
| ▸ | PADI2 | Q9Y2J8 | 1/20 | 0.32 |
| ▸ | MAOA | P21397 | 1/20 | 0.31 |
| ▸ | MAOB | P27338 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10964095 | 0.75 | ALOX15 (0.36) | PTPN1MAOAMAOB | |
| SCHEMBL21819582 | 0.71 | NSD2 (0.43) | NSD2PTPN1HKDC1PADI1PADI3 | |
| SCHEMBL461353 | 0.69 | MAOA (0.31) | MAOAMAOB | |
| SCHEMBL27402272 | 0.69 | — | — | |
| SCHEMBL28210086 | 0.65 | PTPN1 (0.36) | PTPN1MAOAMAOB | |
| SCHEMBL4964070 | 0.65 | NSD2 (0.43) | NSD2PTPN1HKDC1PADI1PADI3 | |
| SCHEMBL10780286 | 0.63 | MAOA (0.50) | MAOAMAOB | |
| SCHEMBL7195409 | 0.63 | MEN1 (0.37) | — | |
| SCHEMBL28422242 | 0.63 | XIAP (0.38) | — | |
| SCHEMBL7196136 | 0.61 | ALDH1A1 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8173806-B2 | Method for production of quinazolin-4-one derivative | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2012-05-08 | — | — | US | disclosed |
| EP-1997812-B1 | METHOD FOR PRODUCTION OF QUINAZOLIN-4-ON DERIVATIVE | MITSUBISHI GAS CHEMICAL CO (JP) | 2011-07-13 | — | — | EP | disclosed |
| US-20090054646-A1 | Method for Production of Quinazolin 4-One Derivative | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2009-02-26 | — | — | US | disclosed |
| EP-1997812-A1 | METHOD FOR PRODUCTION OF QUINAZOLIN-4-ON DERIVATIVE | Mitsubishi Gas Chemical Company, Inc. (JP) | 2008-12-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054646-A1 | Method for Production of Quinazolin 4-One Derivative | NQO2, ALDH7A1, ALAD | NSD2 3529/4885PTPN1 3375/4885HKDC1 1418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.